Cerveau Technologies Signs Agreement with Janssen for Novel Tau Imaging Agent

Company News

Oct. 16th, 2017. (BUSINESS WIRE) - Cerveau Technologies, Inc. has announced a research collaboration agreement with Janssen Pharmaceuticals, Inc. for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, which are made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer's disease.

The collaboration is focused on using [F-18]MK-6240 as a biomarker in Janssen neurodegenerative disease research studies. The parties will collaborate on using [F-18]MK-6240 to diagnose and evaluate new treatments for neurodegenerative diseases in humans.

"Cerveau is focused on enhancing access to key technologies that we believe have the potential to advance brain health," says Rick Hiatt, President and chief executive officer, Cerveau Technologies, Inc. "We are excited by the opportunity to work with Janssen with the goal of expanding the availability of this novel investigational imaging agent globally throughout the broader scientific community."

About Cerveau Technologies, Inc.

Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease.